From the Department of Urology, The Methodist Hospital, Houston, Texas (Dr Miles); the Departments of Pathology & Immunology (Drs Ittmann and Wheeler and Mr Sayeeduddin) and Molecular and Cell Biology (Dr Rowley), Baylor College of Medicine, Houston, Texas; Instituto de Patologia e Investigacion, Asuncion, Paraguay (Dr Cubilla); Biostatistics/Epidemiology/Research Design (BERD) Core, Departments of Internal Medicine (Dr Lee) and Pathology and Laboratory Medicine (Drs Bu, Ding, Gao, and Ayala), University of Texas Health Sciences Center Medical School, Houston.
Arch Pathol Lab Med. 2019 May;143(5):565-570. doi: 10.5858/arpa.2018-0242-RA. Epub 2019 Mar 13.
CONTEXT.—: The combination of grading and staging is the basis of current standard of care for prediction for most cancers. D. F. Gleason created the current prostate cancer (PCa) grading system. This system has been modified several times. Molecular data have been added. Currently, all grading systems are cancer-cell based.
OBJECTIVE.—: To review the literature available on host response measures as reactive stroma grading and stromogenic carcinoma, and their predictive ability for PCa biochemical recurrence and PCa-specific death.
DATA SOURCES.—: Our own experience has shown that reactive stroma grading and the subsequently binarized system (stromogenic carcinoma) can independently predict biochemical recurrence and/or PCa-specific death, particularly in patients with a Gleason score of 6 or 7. Stromogenic carcinoma has been validated by 4 other independent groups in at least 3 continents.
CONCLUSIONS.—: Broders grading and Dukes staging have been combined to form the most powerful prognostic tools in standard of care. The time has come for us to incorporate measures of host response (stromogenic carcinoma) into the arsenal of elements we use to predict cancer survival, without abandoning what we know works. These data also suggest that our current definition of PCa might need some revision.
分级和分期相结合是目前大多数癌症预测的标准治疗基础。D.F.格里森创建了当前的前列腺癌(PCa)分级系统。该系统已经过多次修改。已经添加了分子数据。目前,所有的分级系统都是基于癌细胞的。
回顾有关宿主反应措施的文献,如反应性基质分级和基质源性癌,以及它们对 PCa 生化复发和 PCa 特异性死亡的预测能力。
我们自己的经验表明,反应性基质分级和随后的二值化系统(基质源性癌)可以独立预测生化复发和/或 PCa 特异性死亡,特别是在格里森评分 6 或 7 的患者中。基质源性癌已经被其他 4 个独立的小组在至少 3 个大洲得到验证。
Broders 分级和 Dukes 分期已经结合在一起,形成了标准治疗中最强大的预后工具。现在是我们将宿主反应(基质源性癌)的测量纳入我们用于预测癌症生存的元素库的时候了,同时不放弃我们所知道的有效的方法。这些数据还表明,我们目前对 PCa 的定义可能需要一些修订。